CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Rating of “Moderate Buy” by Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been given an average recommendation of “Moderate Buy” by the nineteen ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $67.7778.

Several analysts have issued reports on CRSP shares. Citizens Jmp restated a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Monday, July 6th. Evercore reissued an “outperform” rating and issued a $76.00 target price on shares of CRISPR Therapeutics in a research note on Monday, May 11th. UBS Group set a $80.00 target price on CRISPR Therapeutics in a report on Friday, June 12th. Wall Street Zen lowered CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 5th. Finally, Morgan Stanley set a $60.00 price target on CRISPR Therapeutics and gave the stock an “equal weight” rating in a research note on Thursday, June 11th.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,786 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its position in shares of CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after purchasing an additional 296 shares in the last quarter. Mcguire Capital Advisors Inc. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $25,000. Ramirez Asset Management Inc. bought a new position in CRISPR Therapeutics during the 4th quarter valued at approximately $26,000. Rothschild Investment LLC increased its position in CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after buying an additional 502 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. raised its stake in CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after buying an additional 382 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 2.1%

Shares of CRSP opened at $46.54 on Friday. The firm’s 50 day simple moving average is $52.66 and its 200 day simple moving average is $52.72. The company has a market capitalization of $4.49 billion, a P/E ratio of -7.48 and a beta of 1.71. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. CRISPR Therapeutics has a 1-year low of $44.12 and a 1-year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. Sell-side analysts forecast that CRISPR Therapeutics will post -4.9 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.